PUBLIC COMPANY
save$VERAVera Therapeutics, Inc.
$VERA30.42-1.84%Brisbane, CA, USupdated 1d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2Monthly Dosing of Atacicept in IgAN
- phase2Atacicept in Multiple Glomerular Diseases
- phase3Atacicept in Subjects With IgA Nephropathy
- phase3Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
- phase2A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
- phase2A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
Insider activity
source: SEC Form 4🐶 Hiring Signal
News
- Roche, Ionis RNA drug scores in kidney disease studyThe results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.biopharma_dive · 11d ago
- Roche kidney drug's Phase 3 win sets up path to accelerated approvalRoche moves closer to entering an increasingly crowded kidney disease market where Novartis, Calliditas, Travere, Otsuka and Vera already have approved drugs. The Swiss pharma reported interim Phas…endpoints · 12d ago
- STAT+: New startup to test psychedelic-like drug against Parkinson’s symptomA psychedelic-like drug for a Parkinson's symptom, mice with half-human brains, and more biotech news in the Readout newsletter.stat · 17d ago
- STAT+: Sen. Warren demands to see Trump drug-pricing pharma contracts, accuses RFK Jr. of hiding themAn FDA pilot program to speed up drug development, Democrats plan health care probes after midterms, and more biotech newsstat · 18d ago
- U.S. reaches highest number of measles deaths in decadesHow the midterms could change health care, the sedative contaminating the fentanyl black market, and other health news from Morning Roundsstat · 18d ago
- 5 biotechs braving the commercial waters with product launchesA growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.biospace · 19d ago
- STAT+: Obesity drugmakers are testing in kids as young as 6Vera seeks kidney drug approval, early data from Syntis Bio, and other biotech news from The Readoutstat · 19d ago
- Vera eyes full approval for Trutakna in IgAN following positive readoutVera Therapeutics said two-year data show its recently approved drug Trutakna stabilized kidney function in patients with a chronic autoimmune disease, setting the drug up for another FDA submissio…endpoints · 20d ago
- STAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trialThe drug stabilized kidney function and reduced the risk of death and other complications in IgAN patientsstat · 20d ago
- Disc sets up polycythemia vera challenge but Silence maintains leadThe polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the…biospace · 23d ago
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that